• Je něco špatně v tomto záznamu ?

Oxime-based 19-nortestosterone-pheophorbide a conjugate: bimodal controlled release concept for PDT

V. Pavlíčková, M. Jurášek, S. Rimpelová, K. Záruba, D. Sedlák, M. Šimková, D. Kodr, E. Staňková, J. Fähnrich, Z. Rottnerová, P. Bartůněk, O. Lapčík, P. Drašar, T. Ruml,

. 2019 ; 7 (36) : 5465-5477. [pub] 20190918

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025652

Photodynamic therapy has become a feasible direction for the treatment of both malignant and non-malignant diseases. It has been in the spotlight since FDA regulatory approval was granted to several photosensitizers worldwide. Nevertheless, there are still strong limitations in the targeting specificity that is vital to prevent systemic toxicity. Here, we report the synthesis and biological evaluation of a novel bimodal oxime conjugate composed of a photosensitizing drug, red-emitting pheophorbide a, and nandrolone (NT), a steroid specifically binding the androgen receptor (AR) commonly overexpressed in various tumors. We characterized the physico-chemical properties of the NT-pheophorbide a conjugate (NT-Pba) and singlet oxygen generation. Because light-triggered therapies have the potential to provide important advances in the treatment of hormone-sensitive cancer, the biological potential of this novel specifically-targeted photosensitizer was assessed in prostatic cancer cell lines in vitro using an AR-positive (LNCaP) and an AR-negative/positive cell line (PC-3). U-2 OS cells, both with and without stable AR expression, were used as a second cell line model. Interestingly, we found that the NT-Pba conjugate was not only photodynamically active and AR-specific, but also that its phototoxic effect was more pronounced compared to pristine pheophorbide a. We also examined the intracellular localization of NT-Pba. Live-cell fluorescence microscopy provided clear evidence that the NT-Pba conjugate localized in the endoplasmic reticulum and mitochondria. Moreover, we performed a competitive localization study with the excess of nonfluorescent NT, which was able to displace fluorescent NT-Pba from the cell interior, thereby further confirming the binding specificity. The oxime ether bond degradation was assayed in living cells by both real-time microscopy and a steroid receptor reporter assay using AR U-2 OS cells. Thus, NT-Pba is a promising candidate for both the selective targeting and eradication of AR-positive malignant cells by photodynamic therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025652
003      
CZ-PrNML
005      
20201222154023.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1039/c9tb01301f $2 doi
035    __
$a (PubMed)31414695
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Pavlíčková, Vladimíra $u Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, 166 28, Prague 6, Czech Republic. silvie.rimpelova@vscht.cz tomas.ruml@vscht.cz.
245    10
$a Oxime-based 19-nortestosterone-pheophorbide a conjugate: bimodal controlled release concept for PDT / $c V. Pavlíčková, M. Jurášek, S. Rimpelová, K. Záruba, D. Sedlák, M. Šimková, D. Kodr, E. Staňková, J. Fähnrich, Z. Rottnerová, P. Bartůněk, O. Lapčík, P. Drašar, T. Ruml,
520    9_
$a Photodynamic therapy has become a feasible direction for the treatment of both malignant and non-malignant diseases. It has been in the spotlight since FDA regulatory approval was granted to several photosensitizers worldwide. Nevertheless, there are still strong limitations in the targeting specificity that is vital to prevent systemic toxicity. Here, we report the synthesis and biological evaluation of a novel bimodal oxime conjugate composed of a photosensitizing drug, red-emitting pheophorbide a, and nandrolone (NT), a steroid specifically binding the androgen receptor (AR) commonly overexpressed in various tumors. We characterized the physico-chemical properties of the NT-pheophorbide a conjugate (NT-Pba) and singlet oxygen generation. Because light-triggered therapies have the potential to provide important advances in the treatment of hormone-sensitive cancer, the biological potential of this novel specifically-targeted photosensitizer was assessed in prostatic cancer cell lines in vitro using an AR-positive (LNCaP) and an AR-negative/positive cell line (PC-3). U-2 OS cells, both with and without stable AR expression, were used as a second cell line model. Interestingly, we found that the NT-Pba conjugate was not only photodynamically active and AR-specific, but also that its phototoxic effect was more pronounced compared to pristine pheophorbide a. We also examined the intracellular localization of NT-Pba. Live-cell fluorescence microscopy provided clear evidence that the NT-Pba conjugate localized in the endoplasmic reticulum and mitochondria. Moreover, we performed a competitive localization study with the excess of nonfluorescent NT, which was able to displace fluorescent NT-Pba from the cell interior, thereby further confirming the binding specificity. The oxime ether bond degradation was assayed in living cells by both real-time microscopy and a steroid receptor reporter assay using AR U-2 OS cells. Thus, NT-Pba is a promising candidate for both the selective targeting and eradication of AR-positive malignant cells by photodynamic therapy.
650    _2
$a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a chlorofyl $x analogy a deriváty $x chemie $x farmakologie $7 D002734
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a lidé $7 D006801
650    _2
$a fluorescenční mikroskopie $7 D008856
650    _2
$a molekulární struktura $7 D015394
650    _2
$a optické zobrazování $7 D061848
650    _2
$a oximy $x chemie $x farmakologie $7 D010091
650    _2
$a velikost částic $7 D010316
650    12
$a fotochemoterapie $7 D010778
650    _2
$a fotosenzibilizující látky $x chemická syntéza $x chemie $x farmakologie $7 D017319
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a povrchové vlastnosti $7 D013499
650    _2
$a testosteron $x analogy a deriváty $x chemie $x farmakologie $7 D013739
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jurášek, Michal
700    1_
$a Rimpelová, Silvie
700    1_
$a Záruba, Kamil
700    1_
$a Sedlák, David
700    1_
$a Šimková, Markéta
700    1_
$a Kodr, David
700    1_
$a Staňková, Eliška
700    1_
$a Fähnrich, Jan
700    1_
$a Rottnerová, Zdeňka
700    1_
$a Bartůněk, Petr
700    1_
$a Lapčík, Oldřich
700    1_
$a Drašar, Pavel
700    1_
$a Ruml, Tomáš
773    0_
$w MED00200167 $t Journal of materials chemistry. B $x 2050-7518 $g Roč. 7, č. 36 (2019), s. 5465-5477
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31414695 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222154018 $b ABA008
999    __
$a ok $b bmc $g 1599797 $s 1116338
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 7 $c 36 $d 5465-5477 $e 20190918 $i 2050-7518 $m Journal of materials chemistry. B $n J Mater Chem B $x MED00200167
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...